BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou J, Jiang X, He S, Jiang H, Feng F, Liu W, Qu W, Sun H. Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms. J Med Chem 2019;62:8881-914. [PMID: 31082225 DOI: 10.1021/acs.jmedchem.9b00017] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 21.3] [Reference Citation Analysis]
Number Citing Articles
1 Chaudhari R, Fong LW, Tan Z, Huang B, Zhang S. An up-to-date overview of computational polypharmacology in modern drug discovery. Expert Opin Drug Discov 2020;15:1025-44. [PMID: 32452701 DOI: 10.1080/17460441.2020.1767063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Haghighijoo Z, Zamani L, Moosavi F, Emami S. Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review. Eur J Med Chem 2022;227:113949. [PMID: 34742016 DOI: 10.1016/j.ejmech.2021.113949] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
3 Jiang X, Zhou J, Wang Y, Chen L, Duan Y, Huang J, Liu C, Chen Y, Liu W, Sun H, Feng F, Qu W. Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer’s disease. European Journal of Medicinal Chemistry 2020;207:112751. [DOI: 10.1016/j.ejmech.2020.112751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wallace-Povirk A, Tong N, Wong-Roushar J, O'Connor C, Zhou X, Hou Z, Bao X, Garcia GE, Li J, Kim S, Dann CE 3rd, Matherly LH, Gangjee A. Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor expressing human tumors. Bioorg Med Chem 2021;37:116093. [PMID: 33773393 DOI: 10.1016/j.bmc.2021.116093] [Reference Citation Analysis]
5 Cao F, Xiao Z, Chen S, Zhao C, Chen D, Haisma HJ, Dekker FJ. HDAC/MIF dual inhibitor inhibits NSCLC cell survival and proliferation by blocking the AKT pathway. Bioorg Chem 2021;117:105396. [PMID: 34649152 DOI: 10.1016/j.bioorg.2021.105396] [Reference Citation Analysis]
6 Martins M, Silva R, M M Pinto M, Sousa E. Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer's Disease. Pharmaceuticals (Basel) 2020;13:E242. [PMID: 32933034 DOI: 10.3390/ph13090242] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
7 Zhuang T, Xiong J, Hao S, Du W, Liu Z, Liu B, Zhang G, Chen Y. Bifunctional μ opioid and σ1 receptor ligands as novel analgesics with reduced side effects. Eur J Med Chem 2021;223:113658. [PMID: 34175542 DOI: 10.1016/j.ejmech.2021.113658] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Meira Menezes T, Assis C, Lacerda Cintra AJ, Silva Dos Santos RC, Martins do Vale WK, Max Gomes Martins R, de Souza Bezerra R, Seabra GM, Li C, Neves JL. Binding Mechanism between Acetylcholinesterase and Drugs Pazopanib and Lapatinib: Biochemical and Biophysical Studies. ACS Chem Neurosci 2021;12:4500-11. [PMID: 34808043 DOI: 10.1021/acschemneuro.1c00521] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Kumar B, Dwivedi AR, Arora T, Raj K, Prashar V, Kumar V, Singh S, Prakash J, Kumar V. Design, Synthesis, and Pharmacological Evaluation of N-Propargylated Diphenylpyrimidines as Multitarget Directed Ligands for the Treatment of Alzheimer's Disease. ACS Chem Neurosci 2022. [PMID: 35797244 DOI: 10.1021/acschemneuro.2c00132] [Reference Citation Analysis]
10 Xie S, Liu J, Tang C, Pang C, Li Q, Qin Y, Nong X, Zhang Z, Guo J, Cheng M, Tang W, Liang N, Jiang N. Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer’s disease. European Journal of Medicinal Chemistry 2020;202:112475. [DOI: 10.1016/j.ejmech.2020.112475] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Knez D, Sosič I, Mitrović A, Pišlar A, Kos J, Gobec S. 8-Hydroxyquinoline-based anti-Alzheimer multimodal agents. Monatsh Chem 2020;151:1111-20. [DOI: 10.1007/s00706-020-02651-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Marcinkowska M, Bucki A, Sniecikowska J, Zagórska A, Fajkis-Zajączkowska N, Siwek A, Gluch-Lutwin M, Żmudzki P, Jastrzebska-Wiesek M, Partyka A, Wesołowska A, Abram M, Przejczowska-Pomierny K, Cios A, Wyska E, Mika K, Kotańska M, Mierzejewski P, Kolaczkowski M. Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia. J Med Chem 2021;64:12603-29. [PMID: 34436892 DOI: 10.1021/acs.jmedchem.1c00497] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhong Y, Chi F, Wu H, Liu Y, Xie Z, Huang W, Shi W, Qian H. Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond. European Journal of Medicinal Chemistry 2022;231:114142. [DOI: 10.1016/j.ejmech.2022.114142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
14 Duan YC, Zhang SJ, Shi XJ, Jin LF, Yu T, Song Y, Guan YY. Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy. Eur J Med Chem 2021;222:113588. [PMID: 34107385 DOI: 10.1016/j.ejmech.2021.113588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Jörg M, Madden KS. The right tools for the job: the central role for next generation chemical probes and chemistry-based target deconvolution methods in phenotypic drug discovery. RSC Med Chem 2021;12:646-65. [PMID: 34124668 DOI: 10.1039/d1md00022e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Remya C, Dileep KV, Koti Reddy E, Mantosh K, Lakshmi K, Sarah Jacob R, Sajith AM, Jayadevi Variyar E, Anwar S, Zhang KYJ, Sadasivan C, Omkumar RV. Neuroprotective derivatives of tacrine that target NMDA receptor and acetyl cholinesterase - Design, synthesis and biological evaluation. Comput Struct Biotechnol J 2021;19:4517-37. [PMID: 34471497 DOI: 10.1016/j.csbj.2021.07.041] [Reference Citation Analysis]
17 Szabó K, Maccari R, Ottanà R, Gyémánt G. Extending the investigation of 4-thiazolidinone derivatives as potential multi-target ligands of enzymes involved in diabetes mellitus and its long-term complications: A study with pancreatic α-amylase. Carbohydr Res 2021;499:108220. [PMID: 33341220 DOI: 10.1016/j.carres.2020.108220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Li J, Hu X, Luo T, Lu Y, Feng Y, Zhang H, Liu D, Fan X, Wang Y, Jiang L, Wang Y, Hao X, Shi T, Wang Z. N-2-(phenylamino) benzamide derivatives as novel anti-glioblastoma agents: Synthesis and biological evaluation. Eur J Med Chem 2021;226:113817. [PMID: 34537445 DOI: 10.1016/j.ejmech.2021.113817] [Reference Citation Analysis]
19 Feldmann C, Yonchev D, Bajorath J. Analysis of Biological Screening Compounds with Single- or Multi-Target Activity via Diagnostic Machine Learning. Biomolecules 2020;10:E1605. [PMID: 33260876 DOI: 10.3390/biom10121605] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
20 Adeowo FY, Oyetunji TP, Ejalonibu MA, Ndagi U, Kumalo HM, Lawal MM. Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment. Chem Biodivers 2021;18:e2100361. [PMID: 34547176 DOI: 10.1002/cbdv.202100361] [Reference Citation Analysis]
21 Guo J, Zhang Y, Zhang C, Yao C, Zhang J, Jiang X, Zhong Z, Ge J, Zhou T, Bai R, Xie Y. N-Propargylamine-hydroxypyridinone hybrids as multitarget agents for the treatment of Alzheimer's disease. Bioorg Chem 2021;113:105013. [PMID: 34062405 DOI: 10.1016/j.bioorg.2021.105013] [Reference Citation Analysis]
22 Shi Y, Zhang H, Song Q, Yu G, Liu Z, Zhong F, Tan Z, Liu X, Deng Y. Development of novel 2-aminoalkyl-6-(2-hydroxyphenyl)pyridazin-3(2H)-one derivatives as balanced multifunctional agents against Alzheimer's disease. Eur J Med Chem 2022;230:114098. [PMID: 35026532 DOI: 10.1016/j.ejmech.2021.114098] [Reference Citation Analysis]
23 Dalvi T, Dewangan B, Agarwal G, Shinde Suchita D, Jain A, Srivastava A, Sahu B. Design, synthesis and in-vitro evaluation of fluorinated triazoles as multi-target directed ligands for Alzheimer disease. Bioorg Med Chem Lett 2021;42:127999. [PMID: 33839248 DOI: 10.1016/j.bmcl.2021.127999] [Reference Citation Analysis]
24 Srivastava A, Fatima K, Fatima E, Singh A, Singh A, Shukla A, Luqman S, Shanker K, Chanda D, Khan F, Negi AS. Fluorinated benzylidene indanone exhibits antiproliferative activity through modulation of microtubule dynamics and antiangiogenic activity. Eur J Pharm Sci 2020;154:105513. [PMID: 32805425 DOI: 10.1016/j.ejps.2020.105513] [Reference Citation Analysis]
25 Pasieka A, Panek D, Jończyk J, Godyń J, Szałaj N, Latacz G, Tabor J, Mezeiova E, Chantegreil F, Dias J, Knez D, Lu J, Pi R, Korabecny J, Brazzolotto X, Gobec S, Höfner G, Wanner K, Więckowska A, Malawska B. Discovery of multifunctional anti-Alzheimer's agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and γ-aminobutyric acid transporters. Eur J Med Chem 2021;218:113397. [PMID: 33838585 DOI: 10.1016/j.ejmech.2021.113397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Fallica AN, Pittalà V, Modica MN, Salerno L, Romeo G, Marrazzo A, Helal MA, Intagliata S. Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective. J Med Chem 2021;64:7926-62. [PMID: 34076441 DOI: 10.1021/acs.jmedchem.0c02265] [Reference Citation Analysis]
27 Li X, Li X, Liu F, Li S, Shi D. Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist. J Med Chem 2021;64:10581-605. [PMID: 34313432 DOI: 10.1021/acs.jmedchem.1c00683] [Reference Citation Analysis]
28 Kumar N, Kumar V, Anand P, Kumar V, Ranjan Dwivedi A, Kumar V. Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease. Bioorg Med Chem 2022;61:116742. [PMID: 35398739 DOI: 10.1016/j.bmc.2022.116742] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
29 Adeowo FY, Lawal MM, Kumalo HM. Design and Development of Cholinesterase Dual Inhibitors towards Alzheimer's Disease Treatment: A Focus on Recent Contributions from Computational and Theoretical Perspective. ChemistrySelect 2020;5:14136-52. [DOI: 10.1002/slct.202003573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Rossi M, Freschi M, de Camargo Nascente L, Salerno A, de Melo Viana Teixeira S, Nachon F, Chantegreil F, Soukup O, Prchal L, Malaguti M, Bergamini C, Bartolini M, Angeloni C, Hrelia S, Soares Romeiro LA, Bolognesi ML. Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease. J Med Chem 2021;64:4972-90. [PMID: 33829779 DOI: 10.1021/acs.jmedchem.1c00048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Behera SK, Vhora N, Contractor D, Shard A, Kumar D, Kalia K, Jain A. Computational drug repurposing study elucidating simultaneous inhibition of entry and replication of novel corona virus by Grazoprevir. Sci Rep 2021;11:7307. [PMID: 33790352 DOI: 10.1038/s41598-021-86712-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Storr T. Multifunctional compounds for the treatment of Alzheimer’s disease. Can J Chem 2021;99:1-9. [DOI: 10.1139/cjc-2020-0279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 He F, Chou CJ, Scheiner M, Poeta E, Yuan Chen N, Gunesch S, Hoffmann M, Sotriffer C, Monti B, Maurice T, Decker M. Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer's Disease Mouse Model. J Med Chem 2021;64:3794-812. [PMID: 33769811 DOI: 10.1021/acs.jmedchem.0c01940] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
34 Qing X, Wang S, Yuan Y, Pei J, Lai L. Multiple Target Drug Design Using LigBuilder 3. Methods Mol Biol 2021;2266:279-98. [PMID: 33759133 DOI: 10.1007/978-1-0716-1209-5_16] [Reference Citation Analysis]
35 Jiang X, Wang Y, Liu C, Xing C, Wang Y, Lyu W, Wang S, Li Q, Chen T, Chen Y, Feng F, Liu W, Sun H. Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer’s disease. Bioorganic & Medicinal Chemistry 2021;30:115940. [DOI: 10.1016/j.bmc.2020.115940] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Gorecki L, Uliassi E, Bartolini M, Janockova J, Hrabinova M, Hepnarova V, Prchal L, Muckova L, Pejchal J, Karasova JZ, Mezeiova E, Benkova M, Kobrlova T, Soukup O, Petralla S, Monti B, Korabecny J, Bolognesi ML. Phenothiazine-Tacrine Heterodimers: Pursuing Multitarget Directed Approach in Alzheimer's Disease. ACS Chem Neurosci 2021;12:1698-715. [PMID: 33852284 DOI: 10.1021/acschemneuro.1c00184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wang Z, Cherukupalli S, Xie M, Wang W, Jiang X, Jia R, Pannecouque C, De Clercq E, Kang D, Zhan P, Liu X. Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. J Med Chem 2022. [PMID: 35175760 DOI: 10.1021/acs.jmedchem.1c01758] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Sun J, Zhong H, Wang K, Li N, Chen L. Gains from no real PAINS: Where 'Fair Trial Strategy' stands in the development of multi-target ligands. Acta Pharm Sin B 2021;11:3417-32. [PMID: 34900527 DOI: 10.1016/j.apsb.2021.02.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
39 Kabir A, Muth A. Polypharmacology: The science of multi-targeting molecules. Pharmacol Res 2022;176:106055. [PMID: 34990865 DOI: 10.1016/j.phrs.2021.106055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
40 Xing K, Zhang J, Han Y, Tong T, Liu D, Zhao L. Design, Synthesis and Bioactivity Evaluation of 4,6-Disubstituted Pyrido[3,2-d]pyrimidine Derivatives as Mnk and HDAC Inhibitors. Molecules 2020;25:E4318. [PMID: 32967084 DOI: 10.3390/molecules25184318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Dorababu A. Promising heterocycle-based scaffolds in recent (2019-2021) anti-Alzheimer's drug design and discovery. Eur J Pharmacol 2022;:174847. [PMID: 35218718 DOI: 10.1016/j.ejphar.2022.174847] [Reference Citation Analysis]
42 Malafaia D, Albuquerque HMT, Silva AMS. Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review. Eur J Med Chem 2021;214:113209. [PMID: 33548635 DOI: 10.1016/j.ejmech.2021.113209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
43 Wang XQ, Zhou LY, Tan RX, Liang GP, Fang SX, Li W, Xie M, Wen YH, Wu JQ, Chen YP. Design, Synthesis, and Evaluation of Chalcone Derivatives as Multifunctional Agents against Alzheimer's Disease. Chem Biodivers 2021;18:e2100341. [PMID: 34510699 DOI: 10.1002/cbdv.202100341] [Reference Citation Analysis]
44 Feldmann C, Philipps M, Bajorath J. Explainable machine learning predictions of dual-target compounds reveal characteristic structural features. Sci Rep 2021;11:21594. [PMID: 34732806 DOI: 10.1038/s41598-021-01099-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 de Lera AR, Ganesan A. Two-hit wonders: The expanding universe of multitargeting epigenetic agents. Current Opinion in Chemical Biology 2020;57:135-54. [DOI: 10.1016/j.cbpa.2020.05.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
46 Jiang X, Guo J, Zhang C, Gu J, Zhou T, Bai R, Xie Y. Discovery of benzamide-hydroxypyridinone hybrids as potent multi-targeting agents for the treatment of Alzheimer's disease. J Enzyme Inhib Med Chem 2021;36:2045-54. [PMID: 34607518 DOI: 10.1080/14756366.2021.1978081] [Reference Citation Analysis]
47 Fronza MG, Sacramento M, Alves D, Praticò D, Savegnago L. 1-(7-Chloroquinolin-4-yl)-N-(4-Methoxybenzyl)-5-Methyl-1H-1,2, 3-Triazole-4- carboxamide Reduces Aβ Formation and Tau Phosphorylation in Cellular Models of Alzheimer's Disease. Neurochem Res 2022. [PMID: 35165799 DOI: 10.1007/s11064-021-03514-8] [Reference Citation Analysis]
48 He M, Ning W, Hu Z, Huang J, Dong C, Zhou HB. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer. Eur J Med Chem 2020;195:112281. [PMID: 32283297 DOI: 10.1016/j.ejmech.2020.112281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
49 Omar YM, Abdel-moty SG, Abdu-allah HH. Further insight into the dual COX-2 and 15-LOX anti-inflammatory activity of 1,3,4-thiadiazole-thiazolidinone hybrids: The contribution of the substituents at 5th positions is size dependent. Bioorganic Chemistry 2020;97:103657. [DOI: 10.1016/j.bioorg.2020.103657] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
50 Chen T, Sun T, Bian Y, Pei Y, Feng F, Chi H, Li Y, Tang X, Sang S, Du C, Chen Y, Chen Y, Sun H. The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases. J Med Chem . [DOI: 10.1021/acs.jmedchem.1c01456] [Reference Citation Analysis]
51 Salerno L, Vanella L, Sorrenti V, Consoli V, Ciaffaglione V, Fallica AN, Canale V, Zajdel P, Pignatello R, Intagliata S. Novel mutual prodrug of 5-fluorouracil and heme oxygenase-1 inhibitor (5-FU/HO-1 hybrid): design and preliminary in vitro evaluation. J Enzyme Inhib Med Chem 2021;36:1378-86. [PMID: 34167427 DOI: 10.1080/14756366.2021.1928111] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Łażewska D, Olejarz-Maciej A, Reiner D, Kaleta M, Latacz G, Zygmunt M, Doroz-Płonka A, Karcz T, Frank A, Stark H, Kieć-Kononowicz K. Dual Target Ligands with 4-tert-Butylphenoxy Scaffold as Histamine H3 Receptor Antagonists and Monoamine Oxidase B Inhibitors. Int J Mol Sci 2020;21:E3411. [PMID: 32408504 DOI: 10.3390/ijms21103411] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Ma H, Huang B, Zhang Y. Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors. Drug Discov Today 2020;25:1682-92. [PMID: 32652312 DOI: 10.1016/j.drudis.2020.07.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
54 Chen X, Shu C, Li W, Hou Q, Luo G, Yang K, Wu X. Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer. J Med Chem 2022. [PMID: 35447031 DOI: 10.1021/acs.jmedchem.2c00063] [Reference Citation Analysis]
55 Zhou Y, Lu X, Du C, Liu Y, Wang Y, Hong KH, Chen Y, Sun H. Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies. Bioorg Med Chem Lett 2021;34:127756. [PMID: 33359445 DOI: 10.1016/j.bmcl.2020.127756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Yumura M, Nagano T, Nishimura Y. Novel Multitarget Therapies for Lung Cancer and Respiratory Disease. Molecules 2020;25:E3987. [PMID: 32882995 DOI: 10.3390/molecules25173987] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
57 Gabr MT, Peccati F. Dual Targeting of Monomeric Tau and α-Synuclein Aggregation: A New Multitarget Therapeutic Strategy for Neurodegeneration. ACS Chem Neurosci 2020;11:2051-7. [PMID: 32579329 DOI: 10.1021/acschemneuro.0c00281] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
58 Feldmann C, Bajorath J. Differentiating Inhibitors of Closely Related Protein Kinases with Single- or Multi-Target Activity via Explainable Machine Learning and Feature Analysis. Biomolecules 2022;12:557. [DOI: 10.3390/biom12040557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Romeo G, Ciaffaglione V, Amata E, Dichiara M, Calabrese L, Vanella L, Sorrenti V, Grosso S, D'Amico AG, D'Agata V, Intagliata S, Salerno L. Combination of Heme Oxygenase-1 Inhibition and Sigma Receptor Modulation for Anticancer Activity. Molecules 2021;26:3860. [PMID: 34202711 DOI: 10.3390/molecules26133860] [Reference Citation Analysis]
60 Rangasamy L, Ortín I, Zapico JM, Coderch C, Ramos A, de Pascual-Teresa B. New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes. ACS Med Chem Lett 2020;11:713-9. [PMID: 32435375 DOI: 10.1021/acsmedchemlett.9b00561] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
61 Li Y, Sang S, Ren W, Pei Y, Bian Y, Chen Y, Sun H. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020). Eur J Med Chem 2021;226:113874. [PMID: 34619465 DOI: 10.1016/j.ejmech.2021.113874] [Reference Citation Analysis]
62 Cantini N, Schepetkin IA, Danilenko NV, Khlebnikov AI, Crocetti L, Giovannoni MP, Kirpotina LN, Quinn MT. Pyridazinones and Structurally Related Derivatives with Anti-Inflammatory Activity. Molecules 2022;27:3749. [PMID: 35744876 DOI: 10.3390/molecules27123749] [Reference Citation Analysis]
63 Feldmann C, Yonchev D, Stumpfe D, Bajorath J. Systematic Data Analysis and Diagnostic Machine Learning Reveal Differences between Compounds with Single- and Multitarget Activity. Mol Pharm 2020;17:4652-66. [PMID: 33151084 DOI: 10.1021/acs.molpharmaceut.0c00901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
64 Sampietro A, Pérez-areales FJ, Martínez P, Arce EM, Galdeano C, Muñoz-torrero D. Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis. Pharmaceuticals 2022;15:545. [DOI: 10.3390/ph15050545] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Kim M, Pandit S, Jee J. Discovery of Kinase and Carbonic Anhydrase Dual Inhibitors by Machine Learning Classification and Experiments. Pharmaceuticals 2022;15:236. [DOI: 10.3390/ph15020236] [Reference Citation Analysis]
66 Liao Q, Li Q, Zhao Y, Jiang P, Yan Y, Sun H, Liu W, Feng F, Qu W. Design, synthesis and biological evaluation of novel carboline-cinnamic acid hybrids as multifunctional agents for treatment of Alzheimer’s disease. Bioorganic Chemistry 2020;99:103844. [DOI: 10.1016/j.bioorg.2020.103844] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
67 El-atawneh S, Goldblum A. Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors. Front Pharmacol 2022;13:812745. [DOI: 10.3389/fphar.2022.812745] [Reference Citation Analysis]
68 Gutti G, Kakarla R, Kumar D, Beohar M, Ganeshpurkar A, Kumar A, Krishnamurthy S, Singh SK. Discovery of novel series of 2-substituted benzo[d]oxazol-5-amine derivatives as multi-target directed ligands for the treatment of Alzheimer's disease. Eur J Med Chem 2019;182:111613. [PMID: 31437780 DOI: 10.1016/j.ejmech.2019.111613] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
69 Cao Z, Song Q, Yu G, Liu Z, Cong S, Tan Z, Deng Y. Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer's disease. Bioorg Med Chem 2021;35:116074. [PMID: 33640707 DOI: 10.1016/j.bmc.2021.116074] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Albertini C, Salerno A, Sena Murteira Pinheiro P, Bolognesi ML. From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology. Med Res Rev 2021;41:2606-33. [DOI: 10.1002/med.21699] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
71 García M, Virgili M, Alonso M, Alegret C, Farran J, Fernández B, Bordas M, Pascual R, Burgueño J, Vidal-Torres A, Fernández de Henestrosa AR, Ayet E, Merlos M, Vela JM, Plata-Salamán CR, Almansa C. Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ1 Receptor Antagonist Clinical Candidate for the Treatment of Pain. J Med Chem 2020;63:15508-26. [PMID: 33064947 DOI: 10.1021/acs.jmedchem.0c01127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
72 Bajorath J. Explainable machine learning for medicinal chemistry: exploring multi-target compounds. Future Med Chem 2022. [PMID: 35775386 DOI: 10.4155/fmc-2022-0122] [Reference Citation Analysis]
73 Makhaeva GF, Serkov IV, Kovaleva NV, Rudakova EV, Boltneva NP, Kochetkova EA, Proshin AN, Bachurin SO. Novel conjugates of 4-amino-2,3-polymethylenequinolines and vanillin as potential multitarget agents for AD treatment. Mendeleev Communications 2021;31:606-8. [DOI: 10.1016/j.mencom.2021.09.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 He X, Zhao L, Zhong W, Chen HY, Shan X, Tang N, Chen CY. Insight into potent leads for alzheimer's disease by using several artificial intelligence algorithms. Biomed Pharmacother 2020;129:110360. [PMID: 32559623 DOI: 10.1016/j.biopha.2020.110360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Stumpfe D, Hoch A, Bajorath J. Introducing the metacore concept for multi-target ligand design. RSC Med Chem 2021;12:628-35. [PMID: 34046634 DOI: 10.1039/d1md00056j] [Reference Citation Analysis]
76 Malafaia D, Oliveira A, Fernandes PA, Ramos MJ, Albuquerque HMT, Silva AMS. Chromeno[3,4-b]xanthones as First-in-Class AChE and Aβ Aggregation Dual-Inhibitors. Int J Mol Sci 2021;22:4145. [PMID: 33923726 DOI: 10.3390/ijms22084145] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Tomaselli D, Mautone N, Mai A, Rotili D. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs). European Journal of Medicinal Chemistry 2020;207:112750. [DOI: 10.1016/j.ejmech.2020.112750] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Godyń J, Zaręba P, Łażewska D, Stary D, Reiner-Link D, Frank A, Latacz G, Mogilski S, Kaleta M, Doroz-Płonka A, Lubelska A, Honkisz-Orzechowska E, Olejarz-Maciej A, Handzlik J, Stark H, Kieć-Kononowicz K, Malawska B, Bajda M. Cyanobiphenyls: Novel H3 receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer's disease. Bioorg Chem 2021;114:105129. [PMID: 34217977 DOI: 10.1016/j.bioorg.2021.105129] [Reference Citation Analysis]
79 Choudhary S, Doshi A, Luckett-Chastain L, Ihnat M, Hamel E, Mooberry SL, Gangjee A. Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer. Bioorg Med Chem 2021;35:116061. [PMID: 33647840 DOI: 10.1016/j.bmc.2021.116061] [Reference Citation Analysis]
80 Feldmann C, Bajorath J. Machine learning reveals that structural features distinguishing promiscuous and non-promiscuous compounds depend on target combinations. Sci Rep 2021;11:7863. [PMID: 33846469 DOI: 10.1038/s41598-021-87042-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
81 Adeowo FY, Ejalonibu MA, Elrashedy AA, Lawal MM, Kumalo HM. Multi-target approach for Alzheimer's disease treatment: computational biomolecular modeling of cholinesterase enzymes with a novel 4-N-phenylaminoquinoline derivative reveal promising potentials. J Biomol Struct Dyn 2021;39:3825-41. [PMID: 33030113 DOI: 10.1080/07391102.2020.1826129] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
82 Stępnicki P, Kondej M, Koszła O, Żuk J, Kaczor AA. Multi-targeted drug design strategies for the treatment of schizophrenia. Expert Opin Drug Discov 2021;16:101-14. [PMID: 32915109 DOI: 10.1080/17460441.2020.1816962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Wang C, Wang X, Wang H, Pu J, Li Q, Li J, Liu Y, Lu L, Jiang S. A "Two-Birds-One-Stone" Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region. J Med Chem 2021;64:11460-71. [PMID: 34261320 DOI: 10.1021/acs.jmedchem.1c00781] [Reference Citation Analysis]
84 Yao C, Jiang X, Zhao R, Zhong Z, Ge J, Zhu J, Ye XY, Xie Y, Liu Z, Xie T, Bai R. HDAC1/MAO-B dual inhibitors against Alzheimer's disease: Design, synthesis and biological evaluation of N-propargylamine-hydroxamic acid/o-aminobenzamide hybrids. Bioorg Chem 2022;122:105724. [PMID: 35305483 DOI: 10.1016/j.bioorg.2022.105724] [Reference Citation Analysis]
85 Chiu W, Chen J, Liu S, Barve IJ, Huang W, Sun C. One‐pot Synthesis of Isoquinoline‐Fused Isoquinolines via Intramolecular Hydroamination/Aza‐Claisen Type Rearrangement Cascade. Adv Synth Catal 2021;363:2834-42. [DOI: 10.1002/adsc.202001576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Zhao Q, Xiong S, Chen C, Zhu H, Xie X, Peng C, He G, Han B. Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity. Front Oncol 2022;12:972372. [DOI: 10.3389/fonc.2022.972372] [Reference Citation Analysis]
87 Zięba A, Stępnicki P, Matosiuk D, Kaczor AA. What are the challenges with multi-targeted drug design for complex diseases? Expert Opin Drug Discov 2022;:1-11. [PMID: 35549603 DOI: 10.1080/17460441.2022.2072827] [Reference Citation Analysis]
88 Gyertyán I. How can preclinical cognitive research further neuropsychiatric drug discovery? Chances and challenges. Expert Opinion on Drug Discovery 2020;15:659-70. [DOI: 10.1080/17460441.2020.1739645] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
89 Lima E, Medeiros J. Marine Organisms as Alkaloid Biosynthesizers of Potential Anti-Alzheimer Agents. Mar Drugs 2022;20:75. [PMID: 35049930 DOI: 10.3390/md20010075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]